Alzinova

Alzinova's strategy to develop a safe and effective treatment for Alzheimer's disease has attracted increasing interest from both the pharmaceutical community and investors. The promising results from the phase 1b study with the vaccine candidate ALZ-101 show that the study achieved both primary and secondary endpoints. In addition, further analysis of the data from the study shows a positive change in biomarkers associated with Alzheimer's disease. 
 
With this positive progress, the company has stepped up its presence at various conferences to expand its contacts with potential investors and big pharmaceutical companies. The goal is to establish global partnerships to further develop the vaccine candidate and accelerate the process of bringing it to market. During the spring, Alzinova will participate in a number of partnering and investor events.
 
Biotech International Convention - US BIO, June 3 – 6
BIO International Convention is the world's largest meeting place for pharmaceutical and biotechnology companies. The event attracts over 14,000 biotechnology and pharmaceutical industry leaders to a week of intensive networking to discover new opportunities, enable collaboration and partnering discussions, and investor meetings. In total, over 3,000 companies from over 30 countries are participating. Alzinova's Business Development Director, Sebastian Hansson, will meet potential partners and present the strong data obtained from the phase 1b study. Read more here: https://www.bio.org/events/bio-international-convention
  
Redeye Investor Forum, May 16
CEO Kristina Torfgård will present at Redeye Investor Forum which is a live broadcast where different companies will hold a 12-minute presentation followed by an 8-minute Q&A session moderated by Redeye analysts. You can ask your question directly to Alzinova during the live broadcast in the questionnaire available on Redeye's website: https://www.redeye.se/events/973447/investor-forum-online-28
 
Carnegie Digital Health Day, Week 23
At the Carnegie Digital Health Day, Azinova's CEO Kristina Torfgård will present the company and the latest developments. The recording will be available on Alzinova's website during week 23. 

Aktiespararna Aktiedagarna, June 11
Kristina Torfgård will present the company at Aktiespararna's event "Aktiedagarna" in Stockholm on June 11. The event is held with both physical participation and through live broadcast where the presentation and Q&A session lasts for about 25 minutes starting at 08.25. For more information about the event: https://www.aktiespararna.se/aktiviteter/aktiedagarna-42149